• STAT+: For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer

    14 days ago - By STAT

    Merck said Thursday that giving its drug Keytruda immediately after surgery significantly reduced the risk of relapse of kidney cancer in patients who had their tumors removed.
    The new clinical trial results make Keytruda the first immunotherapy to show a benefit for this early stage of kidney cancer treatment called the adjuvant setting. Currently, the class of drugs called checkpoint inhibitors are used for patients with more advanced kidney cancer - after it has recurred and spread to other parts of the body. Continue to STAT+ to read the full story...
    Read more ...

     

  • STAT+: Verily's new big hire, Amy Abernethy, on her plans to transform clinical trials - and bring in money

    14 days ago - By STAT

    As personnel moves go, the hiring of Amy Abernethy by Verily is about as big as it gets in digital health care. It signals the Alphabet-backed company's ambition to fundamentally reshape clinical research, making participation easier and drugs more effective.
    Abernethy, an oncologist by training, is credited with modernizing the way the Food and Drug Administration uses and manages data as the former number two at the agency. She essentially helped the FDA catch up, setting up standards for the use of real-world evidence and moving data in the cloud. Continue to STAT+ to read the full story...
    Read more ...